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Introduction: Mammographic density is a strong risk factor for breast cancer overall, but few studies have
examined the association between mammographic density and specific subtypes of breast cancer, especially
aggressive basal-like breast cancers. Because basal-like breast cancers are less frequently screen-detected, it is
important to understand how mammographic density relates to risk of basal-like breast cancer.
Methods: We estimated associations between mammographic density and breast cancer risk according to breast
cancer subtype. Cases and controls were participants in the Carolina Breast Cancer Study (CBCS) who also had
mammograms recorded in the Carolina Mammography Registry (CMR). A total of 491 cases had mammograms
within five years prior to and one year after diagnosis and 528 controls had screening or diagnostic mammograms
close to the dates of selection into CBCS. Mammographic density was reported to the CMR using Breast Imaging
Reporting and Data System categories. The expression of estrogen receptor (ER), progesterone receptor (PR), human
epidermal growth factor receptor 1 and 2 (HER1 and HER2), and cytokeratin 5/6 (CK5/6) were assessed by
immunohistochemistry and dichotomized as positive or negative, with ER+ and/or PR+, and HER2- tumors classified
as luminal A and ER-, PR-, HER2-, HER1+ and/or CK5/6+ tumors classified as basal-like breast cancer. Triple negative
tumors were defined as negative for ER, PR and HER2. Of the 491 cases 175 were missing information on subtypes;
the remaining cases included 181 luminal A, 17 luminal B, 48 basal-like, 29 ER-/PR-/HER2+, and 41 unclassified
subtypes. Odds ratios comparing each subtype to all controls and case-case odds ratios comparing mammographic
density distributions in basal-like to luminal A breast cancers were estimated using logistic regression.
Results: Mammographic density was associated with increased risk of both luminal A and basal-like breast cancers,
although estimates were imprecise. The magnitude of the odds ratio associated with mammographic density was
not substantially different between basal-like and luminal A cancers in case–control analyses and case-case analyses
(case-case OR = 1.08 (95% confidence interval: 0.30, 3.84)).
Conclusions: These results suggest that risk estimates associated with mammographic density are not distinct for
separate breast cancer subtypes (basal-like/triple negative vs. luminal A breast cancers). Studies with a larger
number of basal-like breast cancers are needed to confirm our findings.
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Studies of the molecular profiles of breast cancers have
indicated that breast tumors can be classified into five
etiologically and prognostically relevant subtypes on
the basis of gene expression patterns [1]. Since then lu-
minal A (estrogen receptor (ER)-positive, progesterone
receptor (PR)-positive, and human epidermal growth factor
receptor (HER)-2/neu-negative) and basal-like (ER-negative,
PR-negative, HER-2/neu-negative, and cytokeratin 5/6-
positive and/or HER-1 positive) breast cancers have been
widely studied clinically and epidemiologically [2-14], with
luminal A cancers being of interest because they represent
the largest percentage (45%) of cancers, and basal-like can-
cers, whereas rarer (5 to 15% of cases), having the poorest
survival outcomes [4,15,16]. Basal-like breast cancers are
more prevalent among younger African American women
with breast cancer and show unique risk factor patterns,
often having risk factor-specific associations in the opposite
direction of those for breast cancer overall and luminal
A tumors [4,7-14]. For example, the protective effects of
parity are observed with breast cancers overall and with
luminal breast cancers, but appear to be reversed with
basal-like breast cancer [4]. It is important to understand
how distinct molecular subtypes are related to established
or suspected breast cancer risk factors.
Among breast cancer risk factors, mammographic
density is one of the strongest and most consistent risk
factors, with studies estimating that women with the
highest mammographic density may be at a 4- to 6-fold
increased risk of developing breast cancer compared to
women with the lowest mammographic density [17-24].
However, there are conflicting results on the association
between mammographic density and risk of breast
cancer subtypes defined by hormone receptor status
(reviewed in Boyd et al. [25]). Of the eight case–control
and cohort studies examining the association between
mammographic density and breast cancer risk by tumor
hormonal status, six [26-31] observed increased risk of both
ER- positive (ER+) and ER-negative (ER-) tumors among
those with the most dense breast tissue, and two [32,33]
observed increased risks for ER+ tumors only. Of the
thirteen studies with cases only, all but two [34,35]
concluded that there were no significant differences in
mammographic density by hormone receptor status
[36-46]. A recent meta-analysis on the topic also concluded
that mammographic density is similarly strongly associated
with both ER+ and ER- tumors [47].
Despite these largely negative results, some uncertainty
remains. Notably, recent results suggest that basal-like
breast cancers are associated with decreased involution of
terminal duct lobular units (TDLUs), the structures from
which most breast cancer precursors and cancers develop
[48]. Because elevated mammographic density is also asso-
ciated with decreased TDLU involution [49], it may beexpected that basal-like breast cancers would therefore be
associated with higher mammographic density. However,
data relating mammographic density to specific intrinsic
subtypes are limited [35]. More detailed subtyping that
distinguishes HER2+ tumors from basal-like tumors and
from tumors with poor immunohistochemical (IHC) re-
action due to fixing artifacts is needed. A few studies
have evaluated the association between mammographic
density and three IHC markers (ER, PR, HER-2/neu),
but further resolution of these triple-negative tumors
into those that are truly basal-like would improve these
analyses [26,30,31,40].
We hypothesized that the association between mammo-
graphic density and breast cancer risk would be different
for basal-like versus luminal A breast cancers. We therefore
examined the association between mammographic density
and basal-like and luminal A subtypes of breast cancer
using a panel of five IHC markers. Participants in the
Carolina Breast Cancer Study (CBCS) were matched to
participants in the Carolina Mammography Registry
(CMR) to allow estimation of the association between
mammographic density and risk of these specific breast
cancer subtypes.
Methods
Study setting and population
Subjects in this study were participants in the CBCS who
also had mammograms recorded in the CMR. CBCS is a
population-based, case–control study conducted in 24
counties in North Carolina, designed to identify genetic
and environmental factors for breast cancer risk in African
Americans and Caucasians. Briefly, CBCS participants were
women aged 20 to 74 years; cases were identified from the
North Carolina Central Cancer Registry and controls were
identified using drivers’ license and Medicare beneficiary
lists. Controls were age and race frequency-matched to
cases. The CMR, funded by the Department of Defense
in 1994 and supported as part of the Breast Cancer
Surveillance Consortium by the National Cancer institute
since 1995, is a mammography registry that prospectively
collects data from women and radiologists in mammog-
raphy facilities in community practice. Both CBCS and
CMR are described in detail in Razzaghi et al. [50].
Data from the CBCS and the CMR were combined to
allow for case–control and case-case analyses of mammo-
graphic density by breast cancer subtype. Briefly, CMR and
CBCS were linked using probabilistic linkage with four var-
iables; first and last name, date of birth, and last four digits
of the social security number [51-53]. Breast Imaging
Reporting and Data System (BI-RADS) breast density, age,
and current use of hormone therapy at the time of the
mammogram were collected from the CMR, and all other
participant data were taken from the CBCS. The following
counties from the CBCS were not represented in this
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trols in the CMR: Alamance, Orange, Wake, Johnston,
Lee, Harnett, Bertie, Wilson, Edgecombe, Pitt, Pamlico,
Beaufort, and Tyrell.
Tumor blocks and immunohistochemistry assays
The details of breast cancer subtyping in CBCS have
been published previously [4]. Briefly, all breast cancers
underwent pathology review and descriptive data including
type of biopsy, tumor size, laterality, and other charac-
teristics were abstracted from pathology reports. Three
H&E-stained slides were produced from each of the
paraffin blocks when slices were made for molecular and
IHC analyses. These slides were reviewed in a standardized
fashion by the study pathologist to confirm the diagnosis of
breast cancer and to assign histologic classification [54].
The following markers were used to determine breast can-
cer subtypes: luminal A (ER+ and/or PR+, HER2-), luminal
B (ER+ and/or PR+, HER2+), basal-like (ER-, PR-, HER2-,
HER1+ and/or cytokeratin (CK)5/6+), HER2+/ER- (ER-, PR-,
HER2+), and unclassified (negative for all five markers)
[4,16]. Only luminal A and basal-like cancers are examined
in detail in the current analysis due to the small number of
HER2+ and luminal B cases.
To determine subtype, tumor blocks were sectioned
and stained for a panel of IHC markers at the IHC
Core Laboratory, University of North Carolina (UNC).
Commercially available antibodies to ER, HER2, HER1,
and Cytokeratin 5/6 were used in this study [16,55,56].
For invasive cases, ER/PR status was obtained from
medical records for 80% of cases and determined using
IHC assays performed at UNC for the remaining cases.
For 11% of the cases with missing status for ER/PR on
medical records, paraffin-embedded tissues were used
and ER/PR status was determined at the UNC laboratory
using IHC. ER/PR status was missing for the remaining
9% of the cases [16,54,57].
Of the 491 cases that were in both the CMR and CBCS,
175 had missing information on subtype; the remaining
cases included 181 luminal A, 17 luminal B, 48 basal-like,
29 ER-/PR-/HER2+, and 41 unclassified subtypes.
Mammographic density assessment
Mammographic density was determined by the radiologist
at the time of the mammogram and recorded qualitatively
in the CMR using the BI-RADS scoring system of the
American College of Radiology. BI-RADS density assess-
ment defines four categories of breast tissue composition
including: 1) almost entirely fat, 2) scattered fibroglandular
densities, 3) heterogeneously dense, and 4) extremely dense
[58]. As discussed in Razzaghi et al. [50], for cases density
was reported from the screening or diagnostic mammo-
gram performed within five years prior to or one year after
breast cancer diagnosis. Mammograms for controls werescreening or diagnostic mammograms showing no cancer
within five years prior to and three years after the selec-
tion date. The rationale for choosing a control group with
a broader exposure window has been discussed previously
[50]. Briefly, studies have shown that elevated risks of
breast cancer associated with mammographic density per-
sist for at least 5 years after a mammogram [19,23,59-61].
To assess whether inclusion of diagnostic mammograms
for cases where screening mammograms were unavailable
affected results, we previously conducted sensitivity
analyses. No substantial change in effect estimates for
the association between mammographic density and breast
cancer risk were observed when cases with only diagnostic
mammograms were excluded from analyses [50].
For women with multiple mammograms, the order of
preference was (1) the mammogram prior to breast cancer
diagnosis or selection date into CBCS with the date closest
to diagnosis or selection date and (2) the nearest mammo-
gram after diagnosis/selection. Studies have shown that ele-
vated risks of breast cancer associated with mammographic
density persist for at least 5 years, with studies showing last-
ing effects for 10 years or more for both pre- and postmen-
opausal women [34,59-61]. Mammograms more than one
year following treatment were excluded based on sugges-
tions in the literature that agents used to treat breast cancer
may alter mammographic density as early as 18 months
after initiating therapy [62]. Mammographic density mea-
sured in the CMR is per woman and not per breast. It is
expected that mammographic density measured in this way
reflects risk because mammographic density is a general
marker of breast cancer risk and is not specific to breast
side or location of the eventual cancer [63] and because
density has been shown to be highly correlated between
breasts within a woman [64].
Statistical analysis
Potential confounders were selected based on prior know-
ledge and using directed acyclic graphs (DAGs) [65]. We
adjusted for age, race, body mass index (BMI), hormone
therapy (HT) use, menopausal status, first-degree family
history of breast cancer, age at menarche, and parity
and age at first full-term pregnancy (with the latter two
combined into a single variable). We also adjusted for
an offset term used in the CBCS to oversample young
African American women [66].
The variable coding schemes were chosen for consistency
with previous CBCS publications [4]. As there is substantial
biological and epidemiologic heterogeneity between
BI-RADS 1 and BI-RADS 2 categories, we did not combine
density categories. Rather, we present two models: one
uses BI-RADS 1 as the referent group to show the mag-
nitude of effect comparing each category to this lowest
risk group, and the other uses BI-RADS 2 as the referent
group to increase the stability and/or precision of effect
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comparisons with our previously published investigation
of mammographic density and breast cancer risk [50].
Race was categorized as African American or white based
on self-report. Mammographic density was based on the
four BI-RADS density categories. Age at diagnosis was used
for cases and age at selection into the CBCS for controls
and was analyzed as a continuous variable. BMI was calcu-
lated as body weight (kg)/height2 (m) and was treated as a
continuous variable in the analysis. Age at first full-term
pregnancy and parity/nulliparity were combined to create a
categorical variable that encapsulated both parity status
and age at first birth. HT was categorized as current or
not-current as collected by the CMR at the time of the
mammogram. Because of the association between age, HT
use, and mammographic density, we also examined age
and current HT use at the time of the mammogram
recorded in the CMR, as explained in detail in our previ-
ous study [50]. All categorical variables were coded using
indicator variables.
We used unconditional logistic regression to estimate
the odds ratio (OR) and 95% CI for the association
between mammographic density and breast cancer risk
(SAS version 9.3, SAS Institute, Cary NC, USA). We
considered basal-like and luminal A breast cancers
primarily, but we also examined risk of triple-negative
breast tumors (ER, PR, and HER-2-negative tumors) to fa-
cilitate comparison with previous studies on the association
between mammographic density and risk of triple-negative
breast cancers. Case-case analyses were used to compare
the distribution of mammographic density among patients
with basal-like tumors to that among patients with lu-
minal A tumors, and to compare mammographic density
among triple-negative patients to luminal A patients.
Effect measure modification was not assessed, given
the small sample size.
As addressed in our previous study, to assess the compar-
ability of the CMR-CBCS merged data and the full CBCS
dataset, we compared the characteristics of participants
who matched to the CMR (the current dataset) to those in
the entire CBCS by estimating ORs for established breast
cancer risk factors. The ORs were similar in the CMR-
CBCS merged dataset and the CBCS as a whole for all
variables assessed [50].
Ethical considerations
Both the CMR and the CBCS were approved by the
Institutional Review Board of the UNC and were conducted
in compliance with the Helsinki Declaration. Specific
patient-informed consent was not required for this study,
since all women consented to participate in the CBCS and
the program was authorized to collect and use health and
clinical information from study participants for evaluation
and scientific research.Results
Characteristics of all breast cancer cases (n = 491) and
women with basal-like and luminal A tumors as well as 528
controls are presented in Table 1. Compared with women
with luminal A breast cancer, women with the basal-like
subtype were younger, had higher BMI and waist-to-height
ratio (WHR), were more likely to be African American,
premenopausal, younger than 13 years at menarche, parous
with first full-term pregnancy at younger than 26 years, not
current HT users, users of oral contraceptives, and never
having breastfed (Table 1). Thus, associations with standard
risk factors showed similar patterns by subtype as reported
for the CBCS overall [4].
Table 2 presents the ORs and 95% CIs for adjusted
models with both BI-RADS 1 (model 1) and 2 (model 2)
as the reference groups. Model 1 is included to facilitate
comparison with previous studies that have reported risk
for the BI-RADS 4 group who had ‘extremely dense’
breast tissue, relative to the BI-RADS 1 group who had
‘entirely fatty’ breast tissue, but model 2 allows for more
precise estimates due to a larger referent group. Among
all women, those with extremely dense breasts had an
increased risk of breast cancer compared to women with
entirely fatty breasts and those with scattered fibroglandular
densities (OR 2.45, 95% CI 0.99, 6.09, and OR 1.19, 95% CI
0.72, 1.95, respectively) (Table 2). Model 1 resulted in a
stronger positive case–control association between mam-
mographic density and breast cancer risk for the basal-like
subtype compared to the luminal A subtype (OR 3.6, 95%
CI 0.34, 37.97, and OR 1.98, 95% CI 0.54, 7.34, respectively).
These associations were of weaker magnitude when using
model 2, and associations were of similar magnitude for the
basal-like and luminal A subtypes (OR 1.04, 95% CI 0.34,
3.17, and OR 0.98, 95% CI 0.50, 1.92, respectively) (Table 2).
These results suggest no heterogeneity of breast cancer
risk according to intrinsic subtype; however, the esti-
mates were generally imprecise as evidenced by the
wide confidence intervals.
To facilitate comparisons with previous studies of mam-
mographic density by breast cancer subtype [26,30,39,45],
we also examined the association between density and
breast cancer risk in case–control analyses using the triple-
negative definition of breast cancer. Model 1 resulted in a
large, imprecise estimate for risk of triple negative breast
cancer, and model 2 resulted in a higher odds ratio than
previously observed for basal-like or luminal A breast can-
cers (OR 1.20, 95% CI 0.49, 2.90) (Table 2). To directly
compare basal-like/triple-negative to luminal A breast can-
cers, we used case-case analyses for model 2 (Table 3). As
expected based on case–control analyses, there were no
statistically significant differences between basal-like and lu-
minal A, or between triple-negative and luminal A breast
cancers (OR 1.08, 95% CI 0.30, 3.84, and OR 1.17, 95% CI
0.41, 3.35, respectively) in relation to mammographic
Table 1 Population characteristics by tumor subtype, basal-like and luminal A breast cancers
Variable Overall cases versus controls Cases
Cases Controls Basal-like OR (95% CI) Luminal A OR (95% CI)
Subjects, number 491 528 48 181
Age (CBCS), mean (range), ya 53.2 (28 to 74) 54.0 (31 to 74) 50.2 (33 to 73) 0.99 (0.96, 1.02) 54.5 (31, 74) 1.04 (1.02, 1.06)
BMI, mean (95% CI) 28.6 (15.1, 60.6) 28.8 (14.6, 60.9) 30.9 (19.1 to 44.2) 1.06 (1.02, 1.10) 28.5 (15.0, 52.6) 1.00 (0.98, 1.03)
Number of days, mean (95% CI)b −21 (−1401, 365) 149 (−1617, 1095) −27 (−938, 365) −10 (−1050, 365)
Race, n (%)
White 297 (60.5%) 324 (61.4%) 21 (43.8%) 1.00 116 (64.1%) 1.00
African American 194 (39.5%) 204 (38.6%) 27 (56.3%) 3.32 (1.80, 6.12) 65 (35.9%) 1.31 (0.90, 1.89)
Menopausal status, n (%)
Premenopausal 200 (40.7%) 213 (40.3%) 25 (52.1%) 1.00 67 (37.0%) 1.00
Postmenopausal 291 (59.3%) 315 (59.7%) 23 (47.9%) 0.90 (0.49, 1.65) 114 (63.0%) 1.83 (1.27, 2.65)
Family history, n (%)c
No 386 (81.1%) 440 (85.6%) 39 (83.0%) 1.00 149 (84.2%) 1.00
Yes 90 (18.9%) 74 (14.4%) 8 (17.0%) 1.24 (0.55-2.82) 28 (15.8%) 1.11 (0.67-1.84)
Missing 15 14 1 4
Age at menarche, n (%)
<13 y 257 (52.3%) 230 (43.6%) 32 (66.7%) 1.00 92 (50.8%) 1.00
≥13 y 234 (47.7%) 298 (56.4%) 16 (33.3%) 0.37 (0.19-0.70) 89 (49.2%) 0.76 (0.53-1.09)
Parity and age at FFTP
Nulliparous 74 (15.1%) 67 (12.7%) 6 (12.5%) 1.00 31 (17.1%) 1.00
Parous, <26 y 312 (63.5%) 347 (65.7%) 36 (75.0%) 2.07 (1.04-4.15) 107 (59.1%) 0.93 (0.64-1.34)
Parous, 26+y 105 (21.4%) 114 (21.6%) 6 (12.5%) 0.43 (0.18-1.06) 43 (23.8%) 0.96 (0.63-1.47)
Breastfeeding, n (%)
Never 299 (60.9%) 324 (61.4%) 32 (66.7%) 1.00 110 (60.8%) 1.00
Ever 192 (39.1%) 204 (38.6%) 16 (33.3%) 0.84 (0.44-1.60) 71 (39.2%) 1.09 (0.75-1.57)
Lifetime duration lactation, n (%)
Never 299 (60.9%) 324 (61.4%) 32 (66.7%) 1.00 110 (60.8%) 1.00
>0-3 months 72 (14.7%) 69 (13.1%) 9 (18.8%) 1.71 (0.77-3.79) 26 (14.4%) 1.14 (0.68-1.92)
4+ months 120 (24.4%) 135 (25.6%) 7 (14.6%) 0.50 (0.22-1.16) 45 (24.9%) 1.02 (0.67-1.55)
Current HT use, n (%)d
Yes 129 (26.4%) 181 (35.0%) 9 (18.8%) 1.00 43 (23.9%) 1.00
No 359 (73.6%) 336 (65.0%) 39 (81.2%) 2.36 (1.11-5.05) 137 (76.1%) 1.84 (1.23-2.77)
Missing 3 11 0 1
Oral contraceptive use, n (%)
Never 170 (34.6%) 170 (32.4%) 11 (22.9%) 1.00 72 (39.8%) 1.00
Ever 321 (65.4%) 355 (67.6%) 37 (77.1%) 1.21 (0.59-2.46) 109 (60.2%) 0.49 (0.34-0.71)
Missing 0 3 0 0
WHR, n (%)
<0.77 132 (27.3%) 169 (32.3%) 4 (8.7%) 1.00 45 (25.4%) 1.00
0.77 to 0.83 171 (35.3%) 173 (33.0%) 17 (37.0%) 1.19 (0.63-2.24) 69 (39.0%) 1.41 (0.97-2.05)
≥0.84 181 (37.4%) 182 (34.7%) 25 (54.3%) 2.40 (1.30-4.42) 63 (35.6%) 1.17 (0.80-1.71)
Missing 7 4 2 4
aMean age at diagnosis for cases and selection for controls in the CBCS; bmean number of days between diagnosis date for cases and selection date for controls
in the CBCS, and the date of the mammogram chosen to assess mammographic density; cfirst-degree family history of breast cancer; dcurrent hormone therapy
use at the time of the mammogram. OR, odds ratio; CBCS, Carolina Breast Cancer Study; BMI, body mass index; FFTP, first full-term pregnancy; HT, hormone
therapy; WHR, waist-to-hip ratio; n, number of subjects.
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Table 2 Odds ratios (ORs) and 95% confidence intervals (CIs) for breast cancer risk by tumor subtype associated with
BI-RADS-measured mammographic density
Number of subjects Cases versus controls Triple-negatives versus controls
Controls Cases Model 1a Model 2b TN cases, n Model 1 Model 2
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Almost entirely fat 25 13 1.00 (Referent) 0.48 (0.22, 1.08) 1 1.00 (Referent) 0.17 (0.02, 1.43)
Scattered fibroglandular densities 197 183 2.07 (0.93, 4.59) 1.00 (Referent) 31 5.96 (0.70, 50.64) 1.00 (Referent)
Heterogeneously dense 253 232 2.06 (0.92, 4.60) 1.00 (0.7, 1.35) 40 5.83 (0.68, 50.04) 0.98 (0.5, -1.75)
Extremely dense 53 63 2.45 (0.99, 6.09) 1.19 (0.72, 1.95) 12 7.13 (0.74, 68.90) 1.20 (0.49, 2.90)
Ptrend = 0.24
c Ptrend = 0.31
Basal-like versus controls Luminal A versus controls
BL cases, n Model 1 Model 2 LA cases, n Model 1 Model 2
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Almost entirely fat 1 1.00 (Referent) 0.29 (0.03, 2.51) 4 1.00 (Referent) 0.49 (0.15, 1.59)
Scattered fibroglandular densities 19 3.45 (0.40, 29.90) 1.00 (Referent) 69 2.03 (0.63, 6.59) 1.00 (Referent)
Heterogeneously dense 22 3.03 (0.34, 26.67) 0.88 (0.43, 1.80) 86 2.09 (0.64, 6.79) 1.03 (0.68, 1.56)
Extremely dense 6 3.58 (0.34, 37.97) 1.04 (0.34, 3.17) 22 1.98 (0.54, 7.34) 0.98 (0.50, 1.92)
Ptrend = 0.67 Ptrend = 0.60
aModel 1 is adjusted for age, race, body mass index, menopausal status, family history of breast cancer, age at menarche, use of hormone therapy, and parity and
age at first full-term pregnancy combined, where BI-RADS category 1 (almost entirely fat) is the referent group; bModel 2 is adjusted for the same variables as
Model 1 but BI-RADS category 2 (scattered fibroglandular densities) is the referent group; cP-value for trend test is based on the likelihood ratio test statistic and is
two-sided. The same ordinal model was fit to assess the P-value for trend of Model 1 and Model 2. BI-RADS, Breast Imaging Reporting and Data System; TN,
triple-negative; BL, basal-like; LA, luminal-A; n, number of subjects.
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these case-case analyses are imprecise due to small
case numbers. Thus, based on these findings, there was
no suggestion of etiologic heterogeneity with respect
to mammographic density and subtype.
Discussion
Recent findings of decreased involution of terminal duct
lobular units (TDLU) surrounding basal-like breast cancers
[48] have renewed interest in evaluating the association
between mammographic density and subtype-specific
breast cancer risk. TDLU involution has been inversely
associated with mammographic density [49], leading to the
hypothesis that density may be higher among basal-like
breast cancers. Previous studies evaluating the relationTable 3 Odds ratios (ORs) and 95% confidence intervals (CIs)
BI-RADS-measured mammographic density by breast cancer r
Basal-like versus lum
Model 1a M
OR (95% CI) O
Almost entirely fat 1.00 (Referent) 1.
Scattered fibroglandular densities 0.95 (0.09, 9.90) 1.
Heterogeneously dense 0.63 (0.06, 6.65) 0.
Extremely dense 1.02 (0.08, 13.50) 1.
Ptrend = 0.66
c
aModel 1 is adjusted for age, race, body mass index, menopausal status, family hist
age at first full-term pregnancy combined, where BI-RADS category 1 (almost entire
Model 1 but BI-RADS category 2 (scattered fibroglandular densities) is the referent g
two-sided. The same ordinal model was fit to assess the P-value for trend of Modelbetween mammographic density and breast cancer
subtype have not supported this hypothesis, but these
studies have had significant potential for outcome
misclassification, given the lack of positive markers for
basal-like breast cancer [67]. ER-negative tumors are
clinically heterogeneous, including HER2-positive, basal-
like, and unclassified tumors. Therefore, further strati-
fication of these tumors and identification of basal-like
tumors as distinct from triple-negative tumors (where
all markers failed to show positivity) could help improve
estimates of the true associations. However, even using
five markers in case–control analyses, we observed no
difference in the association between mammographic
density and breast cancer for luminal A, basal-like or
triple-negative breast cancers.for case-case analyses comparing the association with
isk subtypes
inal A Triple-negative versus luminal A
odel 2b Model 1 Model 2
R (95% CI) OR (95% CI) OR (95% CI)
05 (0.10, 10.97) 1.00 (Referent) 0.33 (0.03, 3.95)
00 (Referent) 3.05 (0.25, 36.68) 1.00 (Referent)
67 (0.30, 1.49) 2.62 (0.22, 31.62) 0.86 (0.44, 1.67)
08 (0.30, 3.84) 3.57 (0.26, 49.11) 1.17 (0.41, 3.35)
Ptrend = 0.74
ory of breast cancer, age at menarche, use of hormone therapy, and parity and
ly fat) is the referent group; bModel 2 is adjusted for the same variables as
roup; cP-value for trend test is based on the likelihood ratio test statistic and is
1 and Model 2. BI-RADS, Breast Imaging Reporting and Data System.
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http://breast-cancer-research.com/content/15/5/R76Furthermore, our estimates from case-case analysis,
which can be interpreted as ratios of ORs between the
two subtypes of breast cancer (luminal A and basal-like),
directly estimated the relative strength of association
between the two breast cancer subtypes and showed no
significant difference between basal-like and luminal A
or triple-negative and luminal A breast cancers, similar
to previous results [25,30,39]. Considering previous case-
only studies, eleven of the thirteen studies that examined
mammographic density by hormone receptor status con-
cluded that there were no significant differences [36-46];
only four of these studies (all null) examined the association
using breast cancer subtypes including the triple-negative
subtype [30,40,45,46]. Our previous findings [50] showed
that mammographic density was positively associated with
breast cancer risk overall; here, the stratified analyses for
both luminal A and basal-like breast cancers show similar
effect estimates, such that mammographic density is a risk
factor for both subtypes with no evidence of heterogeneity
by tumor subtype. Using intrinsic subtypes of breast
cancer, our findings were largely consistent with the ma-
jority of prior studies evaluating the relation between
mammographic density and breast cancer risk by molecular
subtypes of breast cancer.
It is possible that there are genetic and heritable factors
that alter mammographic density and breast cancer risk
overall, and are therefore responsible for the association
of mammographic density and breast cancer regardless
of breast cancer subtype [68]. For example, heritable dif-
ferences in exposure or response to hormones and growth
factors may increase proliferative activity and quantities of
stromal and epithelial tissue, with effects on both mammo-
graphic density and breast cancer risk across all subtypes
[68,69]. Consistent with this, two of fourteen established
breast cancer susceptibility loci examined in a recent study
contributed to between-woman differences in mam-
mographic density [70]. This finding suggests a model
that considers mammographic density as an integrated
marker of many different hormonal and non-hormonal
influences on breast tissue composition, and is also sup-
ported by work examining relationships between mammo-
graphic density and non-genetic breast cancer risk factors.
In contrast to mammographic density, many well-
established breast cancer risk factors have shown opposite
effects on basal-like and luminal A subtypes of breast can-
cer [4]. For example, Millikan et al. identified risk factors
for the basal-like subtype, including younger age at diagno-
sis, higher parity, younger age at first full-term pregnancy,
shorter duration of breastfeeding, fewer number of children
breastfed, fewer number of months breastfeeding per child,
and increased WHR ratio [4]. Many other studies have
confirmed similar heterogeneity by anthropometric and
reproductive factors [10,71-75]. Because many of these
variables that have distinct associations with breast cancersubtypes also impact mammographic density, we might
have expected to see differences in the association between
mammographic density and breast cancer subtype. For
example, young age at first full-term pregnancy is associ-
ated with lower mammographic density [76] and a reduc-
tion in risk for luminal A breast cancers [17]. However, it
appears that mammographic density does not have an
association with subtypes that is independent of these
factors. In our models that controlled for these as potential
confounders, there was no evidence of heterogeneity of
the association between mammographic density and
breast cancer by subtype.
Major strengths of our study were reduced outcome
misclassification through use of five markers to identify
breast cancer subtypes (ER, PR, HER2, HER1 and CK5/6)
and linkage of established datasets to allow for a relatively
large study for assessing this association. However, we
note that in the years since the subtyping was performed
on CBCS Phase I and Phase II, several improvements
have been made to further delineate luminal A and lu-
minal B breast cancers. For example, the classification
for luminal B tumors has improved by using the Ki67
index (percentage of Ki67-positive cancer nuclei) [76].
Ideally, these newer markers could be added to improve
identification of luminal B in CBCS 1 and 2, but we have
emphasized luminal A tumors. Results by Bastien et al.
[9] show that ER, PR and HER2 staining are relatively
homogeneous within luminal A cancers (more than 93%
and 94% of luminal A cancers are ER- and PR-positive,
respectively, and more than 99% of these tumors are
HER2-negative). Therefore, it is unlikely that changes in
classification schema would substantially bias the esti-
mates for luminal A reported herein. Moreover, results
from Bastien et al. also show that standard clinical marker,
such as grade, cannot capture the same qualitative infor-
mation that IHC for Ki-67 would obtain. Therefore, fur-
ther delineation of luminal B tumors was not conducted
in this study. Because of our stratification of breast can-
cers into many groups, we share a limitation of most
studies by molecular subtype, namely, small sample size
within strata resulting in imprecise effect-measure esti-
mates for each subtype. In addition, menopausal status
or other hormonal exposures may be important in de-
termining the effects of mammographic density on
breast cancer risk, but we were underpowered to study
effect-measure modification and did not attempt these
analyses. Although our study is limited by small sample
size, this study is the first to have used molecular subtypes
to identify basal-like breast cancers. A pooled analysis or
meta-analysis of the association between mammographic
density and breast cancer subtypes would provide a larger
sample size; however, this will only be possible if future
studies differentiate between basal-like and triple-negative
breast cancers.
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http://breast-cancer-research.com/content/15/5/R76Many recent studies have emphasized etiologic hetero-
geneity by intrinsic subtype. It is important to recognize that
intrinsic subtype classification was greatly influenced by
clinical needs and is based on heterogeneity of tumors long
after the etiologically relevant window has passed. Many
genomic changes occurring late in tumor progression may
not be relevant from an etiologic perspective. While some
studies have found that there is etiologic heterogeneity,
pathogenesis of each subtype is not well-defined and other
markers of heterogeneity may be more relevant for a given
exposure. For example, tumor characteristics that reflect
proliferation or response to DNA damage may be important
if the mechanism of density-associated risk is mitogenesis
or mutagenesis (as suggested by Martin et al. [68]). Alterna-
tively, factors such as hormone receptor status may be more
important etiologically than intrinsic subtype.
Future studies of breast cancer subtypes and mammo-
graphic density by race are desirable, particularly given that
basal-like breast cancers are more prevalent in African
American women and appear to have distinct etiology.
However, based on current data, there is little evidence
to support differences in the effect of mammographic
density by breast cancer subtype.
Conclusions
Using five markers in case–control analyses, we observed
no difference in the association between mammographic
density and breast cancer for luminal A, basal-like or
triple-negative breast cancers. Furthermore, our estimates
from case-case analysis, which directly estimated the
relative strength of association between the two breast
cancer subtypes, showed no significant difference between
basal-like and luminal A, or triple-negative and luminal
A breast cancers.
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